Drugs that contain Ozanimod Hydrochloride
1. List of Zeposia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8481573 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(5 years from now) | |
| US8796318 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9382217 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(5 years from now) | |
| US10239846 | CELGENE INTL | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Nov, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | May 27, 2024 |
| New Chemical Entity Exclusivity (NCE) | Mar 25, 2025 |
NCE-1 date: 2024-03-25
Market Authorisation Date: 25 March, 2020
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Indicated for the tr...
Dosage: CAPSULE;ORAL
ZEPOSIA family patents
30
United States
10
European Union
7
Japan
7
Hungary
6
Korea, Republic of
6
Lithuania
6
China
6
Denmark
6
Spain
6
Portugal
5
Poland
5
Canada
5
Slovenia
5
Brazil
5
Croatia
5
Malaysia
5
EA
5
Australia
5
Israel
4
Mexico
4
New Zealand
4
Cyprus
3
Hong Kong
3
RS
2
Norway
1
Philippines
1
Turkey
1
Netherlands
1
South Africa
1
Austria
1
Singapore
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic